The Goodrich Lab research program is focused on using new methods to stimulate immune response in patients with cancer and to prevent infectious diseases. A clinical application of new technology developed in his lab is for treatment of patients with advanced stage ovarian cancer. In addition, his group is focused on developing methods to generate new vaccine candidates for infectious diseases in humans and animals. The current program of work includes research on new vaccine formulations for SARS-CoV-2, Tuberculosis, Human and Avian Influenza and African Swine Fever, using a technology platform for production of vaccines invented in collaboration with colleagues at Colorado State University.
Publications
Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies
Cardoso M, Ragan I, Hartson L, Goodrich RP. Pathogens. 2023 Jul 5;12(7):911. doi: 10.3390/pathogens12070911. PMID: 37513758
SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.
Bloch EM, Kyeyune D, White JL, Ddungu H, Ashokkumar S, Habtehyimer F, Baker O, Kasirye R, Patel EU, Grabowski MK, Musisi E, Moses K, Hume HA, Lubega I, Shrestha R, Motevalli M, Fernandez RE, Reynolds SJ, Redd AD, Wambongo Musana H, Dhabangi A, Ouma J, Eroju P, de Lange T, Fowler MG, Musoke P, Stramer SL, Whitby D, Zimmerman PA, McCullough J, Sachithanandham J, Pekosz A, Goodrich R, Quinn TC, Ness PM, Laeyendecker O, Tobian AAR. Transfusion. 2023 Jul;63(7):1354-1365. doi: 10.1111/trf.17449. Epub 2023 Jun 16. PMID: 37255467
Pathogen reduction of monkeypox virus in plasma and whole blood using riboflavin and UV light.
Izabela K Ragan, Lindsay M Hartson, Elizabeth J Sullivan, Richard A Bowen, Raymond P Goodrich (2023) PLoS One 18 (1), e0278862
The Mirasol Evaluation of Reduction in Infections Trial (MERIT) : study protocol for a randomized controlled clinical trial.
Aaron Tobian; Ronnnie Kasirye; Heather Hume; Evan Bloch; Irene Lubega; Dorothy Kyeyune; Ruchee Shrestha; Henry Ddungu; Hellen Wambongo Musana; Aggrey Dhabangi; Joseph Ouma; Priscilla Eroju; Telsa de Lange; Michael Tartakovsky; Jodie White; Ceasar Kakura; Mary Glenn Fowler; Philippa Musoke; Monica Nolan; Kate Grabowski; Lawrence Moulton; Susan Stramer; Denise Whitby; Peter Zimmerman; Deo Wabwire; Isaac Kajja; Jeffrey McCullough; Raymond Goodrich; Thomas Quinn; Robert Cortes; Paul Ness (2022) 23(1): 1-13.
Formulating Autologous Therapies for Cancer Autologous: tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
RP Goodrich, A Guth, J Weston, T Opgenorth, G Gordon (2021) BioPharm International 34 (12), 18-20.
more publications